Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CLPP | Q16740 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289366 | 0.89 | CES2 (0.38) | KDM4CALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6288803 | 0.80 | KDM4C (0.33) | KDM4CALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6288793 | 0.80 | ALDH1A1 (0.33) | KDM4CALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6289353 | 0.79 | DAO (0.34) | KDM4CALDH1A1MAPTHSD17B10 | |
| SCHEMBL6289387 | 0.78 | MMP13 (0.39) | ALDH1A1MMP13 | |
| SCHEMBL6288776 | 0.74 | ALDH1A1 (0.34) | KDM4CALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6289332 | 0.74 | ALDH1A1 (0.34) | KDM4CALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6288744 | 0.74 | KDM4C (0.34) | KDM4CALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6700576 | 0.72 | CLPP (0.39) | CLPPPARP1 | |
| SCHEMBL6826383 | 0.69 | CES2 (0.40) | KDM4CALDH1A1MEN1KMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | KDM4C 1177/4885ALDH1A1 337/4885MAPT 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.